Prices Of Formulations Set To Increase From April

New Delhi : Prices of essential medicines – including painkillers, anti-infectives, cardiac drugs and antibiotics – are slated to go up from April, dealing a body blow to consumers already reeling under the impact of inflation.

The government is all set to allow drug companies an increase in line with the change in the annual Wholesale Price Index (WPI). The annual change in WPI, as notified by the government, works out to 12.12% during 2022, the drug prices regulator National Pharmaceutical Pricing Authority (NPPA) said on Monday.

Prices of 384 molecules, which correspond to around 900 formulations across 27 therapies, are expected to go up by over 12%. This is the second year in a row when the increase is more than that allowed for non-scheduled drugs. The 384 molecules, part of the national list of essential medicines, are also known as scheduled drugs, with their prices regulated by the NPPA.

The rest – non-scheduled drugs which are outside price control – are allowed an annual increase of 10% every year. For the year 2021, the subsequent hike in drugs was over 10% in line with change in WPI.

Historically, the increase in prices due to the annual change in WPI has been marginal, ranging between 1% and 2% over the last few years. The NPPA will notify the ceiling prices of the scheduled formulations over the next few days, sources said.

The development will be welcome news for the industry, which has been battling a surge in manufacturing costs on account of multiple factors. During pandemic, the industry was impacted by a rise in prices of raw materials (active pharmaceutical ingredients), freight and increase in plastics and packaging material, among other costs.

“The industry will be relieved once the new prices are notified. It has been facing a cost escalation due to imported raw materials and excipients in certain drugs. Also, it will be a relief for those drugs which were added to the scheduled drugs’ list,” an industry expert said.

  • Related Posts

    • Pharma
    • May 16, 2025
    • 82 views
    Trump targets Big Pharma with drug price order; Indian generics seen gaining edge

    US President Donald Trump’s move to slash prescription drug prices by tying them to rates in countries such as the UK and Germany may rattle multinational pharmaceutical giants, but it…

    • Pharma
    • May 16, 2025
    • 83 views
    Emcutix and Mantra Pharma Introduce Ureaderm: Advanced Urea-Based Moisturizers for Indian Skin

    Emcutix Biopharmaceuticals Ltd in partnership with Canada-based Mantra Pharma Inc—both subsidiaries of Emcure Pharmaceuticals Ltd—has launched Ureaderm 10% and 20%, a new range of urea-based moisturizers designed to address severe dryness…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Trump targets Big Pharma with drug price order; Indian generics seen gaining edge

    Trump targets Big Pharma with drug price order; Indian generics seen gaining edge

    Emcutix and Mantra Pharma Introduce Ureaderm: Advanced Urea-Based Moisturizers for Indian Skin

    Emcutix and Mantra Pharma Introduce Ureaderm: Advanced Urea-Based Moisturizers for Indian Skin

    DCA seizes syrup stocks over misleading fever cure claim

    DCA seizes syrup stocks over misleading fever cure claim

    Mankind Pharma Faces Rs 341.86 Cr Tax Demand

    Mankind Pharma Faces Rs 341.86 Cr Tax Demand